Jagsonpal Pharmaceuticals Intrinsic Value
Jagsonpal Pharmaceuticals (JAGSNPHARM) median intrinsic value is ₹369.23 from 9 valuation models (range ₹58–₹487), vs current price ₹194.62 — +89.7% upside (Trading Below Calculated Value), margin of safety 47.3%. For current market price and key ratios, visit Jagsonpal Pharmaceuticals share price chart.
JAGSNPHARM Valuation Methods Summary — DCF, Graham Number & P/E
Jagsonpal Pharmaceuticals intrinsic value across 9 models vs current price ₹194.62 — upside/downside and value range per method. Browse JAGSNPHARM balance sheet details for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹134.20 | ₹107.36 - ₹161.04 | -31.0% | EPS: ₹6.10, Sector P/E: 22x |
| Book Value Method | asset | ₹369.23 | ₹332.31 - ₹406.15 | +89.7% | Book Value/Share: ₹184.62, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹389.24 | ₹350.32 - ₹428.16 | +100.0% | Revenue/Share: ₹225.38, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹389.24 | ₹350.32 - ₹428.16 | +100.0% | EBITDA: ₹65.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹486.55 | ₹389.24 - ₹583.86 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹58.39 | ₹52.55 - ₹64.23 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹94.84 | ₹85.36 - ₹104.32 | -51.3% | Revenue Growth: 7.3%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹389.24 | ₹350.32 - ₹428.16 | +100.0% | ROE: 17.1%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹159.18 | ₹143.26 - ₹175.10 | -18.2% | EPS: ₹6.10, BVPS: ₹184.62 |
JAGSNPHARM Intrinsic Value vs Market Price — All Valuation Models
Jagsonpal Pharmaceuticals fair value range ₹58–₹487 vs current market price ₹194.62 across 9 valuation models. Compare with JAGSNPHARM DCF to assess whether the stock is under or overvalued.
JAGSNPHARM Intrinsic Value Analysis — Undervalued or Overvalued?
Jagsonpal Pharmaceuticals median intrinsic value ₹369.23, current price ₹194.62 — Trading Below Calculated Value by 89.7%, margin of safety 47.3%.
What is the intrinsic value of JAGSNPHARM?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Jagsonpal Pharmaceuticals (JAGSNPHARM) is ₹369.23 (median value). With the current market price of ₹194.62, this represents a +89.7% variance from our estimated fair value.
The valuation range spans from ₹58.39 to ₹486.55, indicating ₹58.39 - ₹486.55.
Is JAGSNPHARM undervalued or overvalued?
Based on our multi-method analysis, Jagsonpal Pharmaceuticals (JAGSNPHARM) appears to be trading below calculated value by approximately 89.7%.
JAGSNPHARM Financial Health — Key Ratios vs Industry Benchmarks
Jagsonpal Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 13.42 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 17.1% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 19.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.05x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
JAGSNPHARM Cash Flow Quality — Operating & Free Cash Flow
Jagsonpal Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹55 Cr | ₹33 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹35 Cr | ₹23 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹47 Cr | ₹18 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹7 Cr | ₹-6 Cr | Positive Operating Cash Flow | 6/10 |
| March 2021 | ₹28 Cr | ₹27 Cr | Positive Free Cash Flow | 8/10 |